On Jun. 8, 2021, Icosavax announced the first subjects had been dosed with IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain (RBD), in a Phase 1/2 clinical trial.

s previously announced, the Phase 1/2 trial was funded by the Bill & Melinda Gates Foundation. Amgen is manufacturing a key intermediate, and Seqirus is providing its proprietary MF59ﾮ adjuvant for this trial.